Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Protonix Settlement Leaves Question Of How Jury Would Assess At-Risk Launch Damages

This article was originally published in The Pink Sheet Daily

Executive Summary

Teva and Sun are to pay $2.15 billion for their at-risk launch of generic versions of Pfizer’s Protonix; Pfizer says figure represents lost profits and lost royalties from the three years the product faced premature generic competition.

Advertisement

Related Content

ANDA Litigation Soars In 2014-2015; Patent Office Petitions Also Jump
Pfizer Litigation Strategy: Business Focus, Legal Alliance Drive Successes
Teva CFO Sees New Products Coming From Its NTEs & Israel’s R&D Hub
Actavis’ Launch Of Pulmicort Respules Generic Halted By Court
At-Risk Launches: Three Cases May Determine How Damages Are Calculated
Teva Could Face Damages Of $1.2 Billion For At-Risk Launch Of Generic Protonix

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS075818

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel